Therapeutic decision making in a new drug era in multiple sclerosis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Multiple sclerosis is a presumed autoimmune, inflammatory disease of the central nervous system. Since the early 1990s, medications have been devised, tested, and approved for relapsing forms of multiple sclerosis (MS). MS treatments work by altering the immune system to reduce inflammatory MS activity, thus curtailing clinical relapses (attacks), thereby reducing short-term disability related to the MS attacks. The promise of long-term improvement in MS-related disability remains the most desirable therapeutic goal; to what degree current MS therapies are effective in reducing this is controversial. Recent years have seen a surge in novel MS therapies delivered both parenterally and orally that offer new therapeutic alternatives to MS patients and their treating providers. It remains essential to make an unequivocal diagnosis of MS and identify its clinical course prior to initiating therapies. Switching and altering MS therapies can now be done by rational approaches based on therapeutic efficacy and tolerability; however, these remain nonevidence-based for the most part. The high cost of MS therapies remains a significant concern. A new therapeutic era is at hand offering new hope for patients affected by this chronic, frequently disabling disease.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalSeminars in Neurology
Volume33
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Multiple Sclerosis
Decision Making
Pharmaceutical Preparations
Therapeutics
Hope
Autoimmune Diseases
Immune System
Central Nervous System
Hand
Costs and Cost Analysis
Recurrence

Keywords

  • diagnosis
  • multiple sclerosis (MS)
  • therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Therapeutic decision making in a new drug era in multiple sclerosis. / Keegan, B. Mark.

In: Seminars in Neurology, Vol. 33, No. 1, 2013, p. 5-12.

Research output: Contribution to journalArticle

@article{1a117d7ad4d54dd39a73bad2b0f9bed2,
title = "Therapeutic decision making in a new drug era in multiple sclerosis",
abstract = "Multiple sclerosis is a presumed autoimmune, inflammatory disease of the central nervous system. Since the early 1990s, medications have been devised, tested, and approved for relapsing forms of multiple sclerosis (MS). MS treatments work by altering the immune system to reduce inflammatory MS activity, thus curtailing clinical relapses (attacks), thereby reducing short-term disability related to the MS attacks. The promise of long-term improvement in MS-related disability remains the most desirable therapeutic goal; to what degree current MS therapies are effective in reducing this is controversial. Recent years have seen a surge in novel MS therapies delivered both parenterally and orally that offer new therapeutic alternatives to MS patients and their treating providers. It remains essential to make an unequivocal diagnosis of MS and identify its clinical course prior to initiating therapies. Switching and altering MS therapies can now be done by rational approaches based on therapeutic efficacy and tolerability; however, these remain nonevidence-based for the most part. The high cost of MS therapies remains a significant concern. A new therapeutic era is at hand offering new hope for patients affected by this chronic, frequently disabling disease.",
keywords = "diagnosis, multiple sclerosis (MS), therapy",
author = "Keegan, {B. Mark}",
year = "2013",
doi = "10.1055/s-0033-1345709",
language = "English (US)",
volume = "33",
pages = "5--12",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Therapeutic decision making in a new drug era in multiple sclerosis

AU - Keegan, B. Mark

PY - 2013

Y1 - 2013

N2 - Multiple sclerosis is a presumed autoimmune, inflammatory disease of the central nervous system. Since the early 1990s, medications have been devised, tested, and approved for relapsing forms of multiple sclerosis (MS). MS treatments work by altering the immune system to reduce inflammatory MS activity, thus curtailing clinical relapses (attacks), thereby reducing short-term disability related to the MS attacks. The promise of long-term improvement in MS-related disability remains the most desirable therapeutic goal; to what degree current MS therapies are effective in reducing this is controversial. Recent years have seen a surge in novel MS therapies delivered both parenterally and orally that offer new therapeutic alternatives to MS patients and their treating providers. It remains essential to make an unequivocal diagnosis of MS and identify its clinical course prior to initiating therapies. Switching and altering MS therapies can now be done by rational approaches based on therapeutic efficacy and tolerability; however, these remain nonevidence-based for the most part. The high cost of MS therapies remains a significant concern. A new therapeutic era is at hand offering new hope for patients affected by this chronic, frequently disabling disease.

AB - Multiple sclerosis is a presumed autoimmune, inflammatory disease of the central nervous system. Since the early 1990s, medications have been devised, tested, and approved for relapsing forms of multiple sclerosis (MS). MS treatments work by altering the immune system to reduce inflammatory MS activity, thus curtailing clinical relapses (attacks), thereby reducing short-term disability related to the MS attacks. The promise of long-term improvement in MS-related disability remains the most desirable therapeutic goal; to what degree current MS therapies are effective in reducing this is controversial. Recent years have seen a surge in novel MS therapies delivered both parenterally and orally that offer new therapeutic alternatives to MS patients and their treating providers. It remains essential to make an unequivocal diagnosis of MS and identify its clinical course prior to initiating therapies. Switching and altering MS therapies can now be done by rational approaches based on therapeutic efficacy and tolerability; however, these remain nonevidence-based for the most part. The high cost of MS therapies remains a significant concern. A new therapeutic era is at hand offering new hope for patients affected by this chronic, frequently disabling disease.

KW - diagnosis

KW - multiple sclerosis (MS)

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84878309138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878309138&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1345709

DO - 10.1055/s-0033-1345709

M3 - Article

C2 - 23709208

AN - SCOPUS:84878309138

VL - 33

SP - 5

EP - 12

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 1

ER -